As a monotherapy, FAP-RLT is well tolerated with manageable side effects, showing encouraging response to tumors with high levels of FAP expression, such as sarcoma, PDAC, breast cancer, RR-DTC, and lung cancer. The gene discussed is FAP; the disease is lung carcinoma.